This bill directs the Minnesota Commissioner of Health to conduct a comprehensive study on the state's capacity to support innovations in cell and gene therapies for rare diseases. The study will assess various factors, including the state's infrastructure for research and clinical trials, workforce needs, health system capabilities, and policies affecting access to these therapies. The commissioner is required to consult with stakeholders such as the University of Minnesota, the Minnesota Rare Disease Advisory Council, and patient advocacy groups to gather input for the study.

By January 1, 2028, the commissioner must submit a report to the legislature detailing the findings of the study, along with recommendations for strategic investments and policy changes to enhance Minnesota's leadership in rare disease therapies. The bill also includes an appropriation of funds from the general fund for the study, which is a one-time allocation available until June 30, 2028. The report will be made publicly accessible on the Department of Health's website.